{'fraction_non_alphanumeric': 0.02349869451697128, 'fraction_numerical': 0.02349869451697128, 'mean_word_length': 5.182795698924731, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combined High Throughput Screening with QSAR Analysis Unravel Potential Glyoxalase-I inhibitors.

INTRODUCTION
Glyoxalase system is ubiquitous system in human cells which has been examined thoroughly for its role in cancerous diseases. It detoxifies endogenous harmful metabolites, mainly methylglyoxal (MG) into non-toxic bystanders. In previous work, our group has explored a series of compounds against glyoxalase I protein.


METHOD
In this research, highthroughput screening approach was used to investigate the activity of in-house database composed of 205 compounds.


RESULTS
15 compounds were found active as glyoxalase I inhibitors. Structure based model Hypo(2ZA0_2_02) combined with 3D-QSAR modeling were applied to predict glyoxalase I inhibition and to explain their activity. The 15 candidates showed more than 50% inhibition with low micromolar IC50 ranges between 5.0 to 42.0 µM.


CONCLUSION
The compounds have been successfully mapped and fitted the Hypo(2ZA0_2_02) model which explain the presence of anti-glyoxalase I activity. This model could be used in future for further development of new and novel glyoxylase I inhibitors.